title: [Evaluation of bronchial arterial infusion (BAI) for lung cancer with carcinomatous pleuritis].
abstract: METHODS
  Six high-risk patients of lung cancer with carcinomatous pleuritis to which BAI was done were examined. BAI was performed using CDDP (40-50 mg/m2) + CPT-11 (40-50 mg/m2). The therapeutic effects, side effects, a reduction of the symptoms and prognosis were examined.
  
  
  RESULTS
  All cases were revealed as stable disease according to the rule of the RECIST. The side effect of appetite loss for over grade 2 was found in one case. The reduction of respiratory symptoms (cough, dyspnea at the movement in 3, chest pain in 1 and loss of the movement in 1) was recognized by four out of five cases. Five patients died in three to seven months after the treatment of BAI. The causes of death were the recurrence of carcinomatous pleuritis and the primary lesion or the metastasis lesion of the lung in 4 cases and the recurrence of the primary lesion in 1 case. The recurrence of the malignant pleural effusion was recognized in 1 case without intra-thoracic infusion.
  
  
  CONCLUSIONS
  BAI was effective as a reduction of the respiratory symptoms in the high-risk patients of lung cancer with carcinomatous pleuritis. It appeared that a long-term survival was probable with the combination of BAI, intra-thoracic infusion and systemic chemotherapy.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Otsuka Hospital.
authors.forename: Haruya
authors.initials: H
authors.lastname: Koshiishi
authors.forename: Eisuke
authors.initials: E
authors.lastname: Takahashi
authors.forename: Keita
authors.initials: K
authors.lastname: Koseki
authors.forename: Kenichirou
authors.initials: K
authors.lastname: Mori
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Goto
authors.forename: Takashi
authors.initials: T
authors.lastname: Okamura
authors.forename: Tomohito
authors.initials: T
authors.lastname: Minami
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Tamamoto
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Sakaniwa
authors.forename: Naganobu
authors.initials: N
authors.lastname: Hayashi
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Koshiishi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D010998:Pleurisy / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D014057:Tomography, X-Ray Computed
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin